Journal of Managed Care & Specialty Pharmacy

Article	Citations
Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs	117
“It’s Time to Represent”: shifting the paradigm to improve the quality of inputs into value assessment frameworks	21
Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation	16
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	15
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia	14
Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study	14
Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey	14
Innovation is the driver behind quality improvements in diabetes care delivery	12
Impact of continuous glucose monitoring on emergency department visits and all-cause hospitalization rates among Medicaid beneficiaries with type 2 diabetes treated with multiple daily insulin or basa	12
THE MOST FAVORED NATIONS MODEL INTERIM FINAL RULE IS FATALLY FLAWED AND MUST BE RESCINDED—YET THE PROBLEM IT ADDRESSES DEMANDS A SOLUTION	11
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions	11
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) stu	11
Cost sharing: implications of a well-intended benefits strategy	10
Cardiovascular risk prediction model and stratification in patients with type 2 diabetes enrolled in a Medicare Advantage plan	10
Clinical and economic impact of primary hyperoxaluria: a retrospective claims analysis	10
Prescription digital therapeutics: Applying Medicaid experience to value assessment and formulary management	10
Racial and ethnic disparities due to Medicare Part D Star Ratings criteria among kidney transplant patients with diabetes, hypertension, and/or dyslipidemia	10
Qualitative exploration of factors influencing the plan selection process by Medicare beneficiaries	10
Direct-acting antiviral retreatment patterns for hepatitis C	9
Reducing disparities in medication use: Responding to managed care pharmacy’s imperatives	9
CFTR modulators: transformative therapies for cystic fibrosis	9
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis	9
Managing high-priced biologic agents: challenges and potential solutions	8
A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?	8
FDA expedited approval and implications for rational formulary and health plan design	8

Payer perceptions on the use of economic models in oncology decision making	8
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments	8
RESPONSE TO: COST-SHARING: IMPLICATIONS OF A WELL-INTENDED BENEFITS STRATEGY	8
What is needed to sustain comprehensive medication management? One health plan’s perspectives	8
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis	7
Building health plan–pharmacist provider partnerships to optimize medication outcomes	7
The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations	7
Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study	7
Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions	7
Comparison of time to treatment initiation of specialty medications between an integrated health system specialty pharmacy and external specialty pharmacies	7
Understanding differences between what alternate propensity score methods estimate	7
Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients	6
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs	6
Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation	6
Striving for Affordable Medicine: Lessons in Price Negotiation Learned from the United Kingdom	6
Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors	6
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States	6
Underprescribing vs underfilling to oral anticoagulation: An analysis of linked medical record and claims data for a nationwide sample of patients with atrial fibrillation	6
Productivity loss by cancer stage in patients newly diagnosed with hepatocellular carcinoma: A claims database analysis	6
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 3	6
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder	6
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study	6
Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population	6
Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases	5
Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States	5
Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy	5
Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy	5
The implementation of value-based frameworks, clinical care pathways, and alternative payment models for cancer care in the United States	5
Medication and bone health in multiple sclerosis: A systematic review and meta-analysis	5
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer	5
Evaluation of financial outcomes under a value-based payment program for community pharmacies	5
Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus	5
Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis	5
Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States	5
Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist	5
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program	5
Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage	5
COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data	5
Racial and social inequities in medication use: A review of articles responding to the Journal of Managed Care + Specialty Pharmacy’s Call to Action	5
Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries	5
Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis	5
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it	5
Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study	4
An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database	4
Comparing and validating medication complexity from insurance claims against electronic health records	4
Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis	4
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy	4
Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration	4
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance	4
Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder	4

Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression	4
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults	4
Poster Abstracts - Academy of Managed Care Pharmacy 2023	4
Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis	4
The effectiveness and value of aducanumab for Alzheimer’s disease	4
Is it time to replace the star ratings adherence measures?	4
Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes	4
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	4
Direct health care costs associated with COVID-19 in the United States	4
Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospectiv	4
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis	4
Advancing a managed care pharmacy research agenda: Generating real-world evidence to support US Food and Drug Administration Accelerated Approvals and improving benefit design to address health inequi	4
Specialty drug and health care utilization vary by wage level in employer-sponsored health plans	4
The evolution of payer management of oncology drugs in the United States between 2017 and 2022	4
Drugs likely subject to Medicare negotiation, 2026-2028	4
Striving for affordable medicine: Lessons in price negotiation learned from the United Kingdom	4
Need for payer-provider partnerships in addressing social determinants of health	4
Prevalence, incidence, and treatment patterns of fistulizing Crohn disease: A US population-based cohort study	4
Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer	4
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness	4
Correction	4
Oral treatments for outpatient COVID-19: Effectiveness and value	4
Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration	3
Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis	3
A summit on amplifying voices of patients, caregivers, and people with disabilities in Inflation Reduction Act drug price negotiations	3
Perceptions of prior authorization by use of electronic prior authorization software: A survey of providers in the United States	3
Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis	3
Impact of a diabetes remote monitoring program on medication adherence	3
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States	3
Associations between pharmacy choice and influenza vaccination: Mail order vs community pharmacy users	3
Implementation of an adherence pharmacy referral protocol for patients taking sacubitril/valsartan	3
Social needs of dual-enrolled Medicare-Medicaid patients with medication nonadherence in a telehealth medication therapy management program	3
Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018	3
Ensuring a high-quality and resilient supply chain of essential medications means paying more	3
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis	3
Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study	3
The effectiveness and value of novel treatments for cystic fibrosis	3
Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States	3
Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure	3
Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States	3
Impact of a human papillomavirus vaccination clinical program in a commercially insured population	3
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma	3
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data	3
Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies	3
Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States	3
JMCP’S MISSION AND GUIDING PRINCIPLES	3
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	3
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases	3
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol	3
Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective	3
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease	3
Emerging trends in information technology: Perspectives on the 2024 AMCP Foundation Survey	3
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	3
Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies	3
Web-based patient portal use and medication overlap from VA and private-sector pharmacies among older veterans	3
The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018	3
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	3
Corrections	3
Budget impact of lasmiditan for the acute treatment of migraine in the United States	3
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma	3
Chronic graft-vs-host disease: Current understanding of disease and treatment landscape	3
The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective	3
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions	3
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States	3
Trends in Medicaid spending on inhalers in the United States, 2012-2018	3
Analysis of a panel-based pharmacogenomics testing program among members of a commercial and Medicare client of a pharmacy benefits manager	3
Statin use and mortality in rheumatoid arthritis: an incident user cohort study	3
Poster Abstracts - Academy of Managed Care Pharmacy 2024	3
Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans	3
Payer perceptions of the use of real-world evidence in oncology-based decision making	3
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	2
DISCARDED MEDICATIONS IN VIALS ARE A SYMPTOM OF OUR HEALTH CARE SYSTEM: A CALL TO ACTION	2
Characterizing health plan evidence review practices	2
Validation of EHR medication fill data obtained through electronic linkage with pharmacies	2
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model	2
Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023	2
Pharmacoequity measurement framework: A tool to reduce health disparities	2
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel	2
The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD	2
Annual costs among patients with major depressive disorder and the impact of key clinical events	2

Proposal for capturing patient experience through extended value frameworks of health technologies	2
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations	2
The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy	2
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States	2
Cost burden of cirrhosis and liver disease progression in metabolic dysfunction–associated steatohepatitis: A US cohort study	2
Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression	2
COMMENT ON MODEL INPUTS AND ASSUMPTIONS FOR THE COST-MINIMIZATION MODEL USED TO COMPARE COST OF BIOLOGICS IN SEVERE ASTHMA	2
Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States	2
Health insurance coverage and switching among people with hemophilia A in the United States	2
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States	2
The potential role of real-world evidence in Centers for Medicare & Medicaid Services’ future price negotiations: Recommendations for a robust framework	2
Prescription drug coverage satisfaction, cost-reducing behavior, and medication nonadherence among Medicare beneficiaries with type 2 diabetes	2
The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group	2
The effectiveness and value of belimumab and voclosporin for lupus nephritis	2
Schizophrenia population health management: perspectives of and lessons learned from population health decision makers	2
Real-world primary nonadherence to antiobesity medications	2
Understanding racial disparities in health care expenditures for cervical cancer	2
Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis	2
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States	2
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study	2
The role of integrated medical and prescription drug plans in addressing racial and ethnic disparities in medication adherence	2
Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities	2
Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis	2
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions	2
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit	2
Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors	2
Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States	2
Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States	2
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy	2
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis	2
Correction	2
Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States	2
THE AUTHORS RESPOND	2
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative	2
Health care costs and resource use of managing hemophilia A: A targeted literature review	2
The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	2
Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada	2
Xanomeline-Trospium in schizophrenia: A detailed review and comparison with the Institute for Clinical and Economic Review’s analysis	2
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B	2
“It’s Time to Represent”: shifting the paradigm to improve the quality of inputs into value assessment frameworks	2
Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis	2
Relationship between social determinants of health and hospitalizations and costs among patients with bipolar disorder 1	2
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program	2
Using latent class and quantum models to value equity in health care: a tale of 2 stories	2
Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure	2
A primer on copay accumulators, copay maximizers, and alternative funding programs	2
Cost-benefit analysis with return on investment of clinical pharmacists in the Military Health System	2
Pharmacists as accessible health care providers: quantifying the opportunity	2
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis	2
Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis	2
Atidarsagene autotemcel for metachromatic leukodystrophy	2
The direct and indirect costs of adult atopic dermatitis	2
Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate	2
Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics	2
Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries	2
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schi	2
Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia	2
The cost impact of disease progression to metastatic castration-sensitive prostate cancer	2
The effectiveness and value of sotatercept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Counci	2
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective	2
Geographic atrophy and factors associated with disease progression among Medicare Advantage enrollees	2
Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis	2
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria	2
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia	2
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States	2
Best practices in designing preapproval information engagements for US health care decision makers	2
Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States	2
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects	2
Incremental cost burden among patients with severe uncontrolled asthma in the United States	2
AMCP Format for Formulary Submissions 5.0	1
Social determinants of health and adult influenza vaccination: a nationwide claims analysis	1
The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B	1
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system	1
Trends in add-on medications following metformin monotherapy for type 2 diabetes	1
Economic burden of recurrent hyperkalemia in patients with chronic kidney disease	1
Using latent class and quantum models to value equity in health care: a tale of 2 stories	1
Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers	1
Clinical and economic evaluation of tralokinumab for atopic dermatitis	1
Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis	1
Gene therapies for sickle cell disease: Effectiveness and value	1
Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States	1
Dose escalation of biologics in biologic-naive patients with Crohn’s disease: Outcomes from the ODESSA-CD study	1
Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study	1
Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs	1
Association between multiple sclerosis disease severity and adherence to disease-modifying therapies	1
Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them	1
Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy	1
Impact of a pharmaceutical care incentive program on the asthma medication ratio among pediatric patients with persistent asthma enrolled in a Medicaid program	1
The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia	1
Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspectiv	1
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States	1
Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines	1
Payer approval and rejection of oral anticoagulant prescriptions and prescription abandonment patterns among patients with venous thromboembolism	1
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States	1
Medicare Part D low-income subsidies expanded in January 2024, but more needs to be done to ensure that eligible beneficiaries enroll	1